novo nordisk tirzepatide sues Eli Lilly for false advertising over weight loss drug comparisons. Get the details Lilly goes toe-to-toe with Novo

Glucagon-like peptide-1 regulation by food proteins and protein hydrolysates

Research has demonstrated sustained growth hormone release following administration: Enhanced binding affinity to GHRH receptors compared to native GHRH Increased resistance to dipeptidyl peptidase-IV enzymatic degradation Sustained elevation of plasma growth hormone concentrations for several hours post-administration Dose-dependent increases in both growth hormone and IGF-1 levels Studies have shown that CJC-1295 increases plasma growth hormone levels by 2- to 10-fold for up to 6 days, with IGF-1 levels remaining elevated for 9-11 days following a single dose in human subjects

As GLP-1 therapy leads to weight loss, improved glycemic control, and potentially reduced inflammation, visceral fat deposits may decrease along with fat in other areas

Find out why salvaging niacinamide is critical to sustaining NAD + levels